Clinical Trial

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Study acronym: ASTERIA

Terminated Phase 2

View on ClinicalTrials.gov →

Why the trial stopped

This decision is based on strategic portfolio prioritization

Summary

The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.

Protocol Amendment History 6 changes

critical Trial terminated 2026-08-08

critical Trial terminated: This decision is based on strategic portfolio prioritization 2026-08-08

notable Enrollment reduced: 60 -> 8 participants 2026-08-08

notable Trial sites reduced: 45 -> 6 locations 2026-08-08

notable Primary completion moved earlier: 2027-01-08 -> 2026-06-24 2026-08-08

minor Completion moved earlier: 2027-11-11 -> 2026-06-24 2026-08-08

Trial Details

NCT Number	NCT07037420
Lead Sponsor	Alexion Pharmaceuticals, Inc.
Conditions	Acromegaly
Enrollment	8 participants
Start Date	2025-10-28
Primary Completion	2026-06-24 (estimated)
Study Completion	2026-06-24 (estimated)
Updated on ClinicalTrials.gov	2026-08-07